Want to see SMMT full AI Analyst Report?
SMMT Stock Chart & Stats
$13.66
-$0.55(-4.06%)
At close: 4:00 PM EDT
$13.66
-$0.55(-4.06%)
Day’s Range― - ―
52-Week Range$12.25 - $30.05
Previous Close$13.23
Volume4.23M
Average Volume (3M)4.74M
Market Cap
$11.17B
Enterprise Value$10.67K
Total Cash (Recent Filing)$690.68M
Total Debt (Recent Filing)$20.38M
Price to Earnings (P/E)―
Beta3.10
Next Earnings
Nov 11, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding797,749,600
10 Day Avg. Volume3,764,348
30 Day Avg. Volume4,737,289
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)26.74
Price to Sales (P/S)0.00
P/FCF Ratio-54.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.68Price Target Upside102.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$3.90M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressFDA acceptance of a BLA and a defined PDUFA date materially de-risks a lead program versus earlier-stage assets. Coupled with Phase III OS benefit (HR 0.76), this creates a credible pathway to approval, enabling potential milestone receipts, commercialization planning and durable value capture across markets.
Broad Phase III FootprintA multi-tumor, global registrational program diversifies indication risk and enlarges addressable markets. Expanding into bladder cancer and maintaining 16 Phase III trials increases the chance of multiple approvals and long-term commercial opportunities, strengthening the drug’s strategic importance.
Balance Sheet StrengthA substantial cash reserve and very low leverage provide meaningful runway to fund ongoing registrational trials and regulatory activities without immediate reliance on dilutive financing. Improved capitalization increases operational flexibility and supports execution of multi-region development plans.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow is a structural weakness for a pre-revenue biotech. Continued burn requires management to secure funding to complete registrational programs, raising dilution risk or forcing program trade-offs that could impair long-term execution and commercialization timing.
Ongoing Equity Funding RiskAn active ATM facility provides funding flexibility but signals reliance on equity markets. Over the medium term, periodic share issuance can dilute existing holders, alter capital structure, and constrain strategic choices if market conditions compel funding at unfavorable prices.
Revenue Concentration On PartnershipsAs a clinical-stage company without recurring product sales, revenue depends on milestone and partner payments. This model concentrates commercial risk in collaborators, limits margin capture and recurring cash flow predictability, and ties long-term revenue outcomes to partner execution and geography-specific rights.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $12.25 and its highest was $30.05 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $11.17B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 88 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Jul 23, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.274 by -$0.006.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 797,749,600 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.274. Following the earnings report the stock price went down -8.812%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.68 (102.64% Upside)
$27.68 (102.64% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 80%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth $103.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
132.13%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress for ivonescimab — multiple positive Phase III PFS readouts, overall survival hazard ratios consistently under 0.80, extensive global clinical activity, commercial exposure in China, and a strong cash balance with no debt. Key near-term catalysts include the FDA PDUFA date (Nov 14, 2026) and upcoming HARMONi-3 interim analyses. Offsetting risks include accelerating operating costs and cash burn, reliance on ATM financings, regulatory uncertainty around statistically significant OS for approval, and the statistical/operational complexity introduced by multiple interim OS looks and regional maturity differences. Overall, the positives around clinical data and pipeline breadth outweigh the financial and regulatory risks presented on the call.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$27.68
▲(102.64% Upside)